Genesis Research Group Names Vera Frajzyngier as Vice President, Head of Real-World Evidence

Genesis Research Group has appointed Vera Frajzyngier, PhD, as Vice President and Head of Real-World Evidence (RWE). This move is aimed at further strengthening the company’s delivery of integrated evidence strategies across development and commercialization.

Frajzyngier brings a wealth of experience to Genesis, having worked in scientific consulting, biopharmaceutical industry leadership, and global health research for over two decades. Most recently, she served as Vice President and Group Head of Regulatory RWE and Pregnancy at Datavant, where she led scientific teams delivering regulatory-grade real-world evidence and pharmacoepidemiology studies for life sciences organizations worldwide.

Prior to her role at Datavant, Frajzyngier spent nearly a decade working in epidemiology divisions within the pharmaceutical industry, including positions at Pfizer and Boehringer Ingelheim. Throughout her career, she has designed and delivered evidence-generation strategies to support product development, regulatory decision-making, safety evaluation, and post-marketing evidence needs across a wide range of therapeutic areas. She has led global scientific teams, advised on regulatory engagements, and delivered studies spanning immunology, oncology, vaccines, infectious disease, hepatology, dermatology, and rare diseases.

Sarah Alwardt, Executive Vice President of RWE/HEOR at Genesis, expressed enthusiasm about Frajzyngier's appointment.

Genesis Research Group’s focus on integrating RWE and other evidence strategies underscores its commitment to supporting clients in making informed decisions throughout the product lifecycle. With Frajzyngier at the helm, the company aims to enhance its capabilities in delivering robust and actionable evidence to support its clients' needs.